0001209191-20-016805.txt : 20200305
0001209191-20-016805.hdr.sgml : 20200305
20200305195623
ACCESSION NUMBER: 0001209191-20-016805
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200303
FILED AS OF DATE: 20200305
DATE AS OF CHANGE: 20200305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wooster Richard
CENTRAL INDEX KEY: 0001774790
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38550
FILM NUMBER: 20692318
MAIL ADDRESS:
STREET 1: C/O TRANSLATE BIO, INC.
STREET 2: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Translate Bio, Inc.
CENTRAL INDEX KEY: 0001693415
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 611807780
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-945-7361
MAIL ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: RaNA Therapeutics, Inc.
DATE OF NAME CHANGE: 20161228
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-03
0
0001693415
Translate Bio, Inc.
TBIO
0001774790
Wooster Richard
C/O TRANSLATE BIO, INC.
29 HARTWELL AVE
LEXINGTON
MA
02421
0
1
0
0
Chief Scientific Officer
Stock Option (right to buy)
7.66
2020-03-03
4
A
0
150000
0.00
A
2030-03-02
Common Stock
150000
150000
D
This option will vest as to 25% of the shares on March 3, 2021, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 3, 2024.
/s/ Paul D. Burgess, as attorney-in-fact
2020-03-05